NARI - Inari Medical, Inc.
NASDAQ
->
Healthcare
->
Medical Devices
Irvine,
United States
Type: Equity
NARI price evolution
NARI
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $70.19 | $67.21 | $39.21 | |
| Short term investments | $39.55 | $34.59 | $76.86 | |
| Net receivables | $84.4 | $81.63 | $78.62 | $70.12 |
| Inventory | $55.21 | $49.36 | $44.65 | $42.9 |
| Total current assets | $263.39 | $249.35 | $233.31 | $235.56 |
| Long term investments | ||||
| Property, plant & equipment | $72.4 | $71.83 | $68.37 | $69.34 |
| Goodwill & intangible assets | $347.51 | $355.42 | $365.22 | |
| Total noncurrent assets | $423.58 | $428.46 | $438.67 | |
| Total investments | $39.55 | $34.59 | $76.86 | |
| Total assets | $697.24 | $672.93 | $661.78 | $674.24 |
| Current liabilities | ||||
| Accounts payable | $15.52 | $16.38 | $12.03 | $10.58 |
| Deferred revenue | ||||
| Short long term debt | $1.92 | $1.72 | $1.69 | |
| Total current liabilities | $148.78 | $138.26 | $86.04 | $76.34 |
| Long term debt | $31.23 | $29.77 | $30.36 | |
| Total noncurrent liabilities | $110.86 | $128.51 | $132.99 | |
| Total debt | $33.15 | $31.49 | $32.05 | |
| Total liabilities | $262.48 | $249.12 | $214.55 | $209.32 |
| Shareholders' equity | ||||
| Retained earnings | -$122.4 | -$104.04 | -$72.69 | -$48.49 |
| Other shareholder equity | $13.14 | -$0.84 | $1.52 | $8.88 |
| Total shareholder equity | $423.81 | $447.23 | $464.91 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $39.21 | $60.22 | $92.75 | $114.62 |
| Short term investments | $76.86 | $266.18 | $83.35 | $49.98 |
| Net receivables | $70.12 | $58.61 | $42.35 | $28.01 |
| Inventory | $42.9 | $32.58 | $21.05 | $10.6 |
| Total current assets | $235.56 | $422.9 | $245.2 | $205.67 |
| Long term investments | $3.98 | |||
| Property, plant & equipment | $69.34 | $72.36 | $61.38 | $7.5 |
| Goodwill & intangible assets | $365.22 | |||
| Total noncurrent assets | $438.67 | $81.25 | $66.34 | $8.42 |
| Total investments | $76.86 | $266.18 | $87.33 | $49.98 |
| Total assets | $674.24 | $504.15 | $311.54 | $214.09 |
| Current liabilities | ||||
| Accounts payable | $10.58 | $7.66 | $6.54 | $3.05 |
| Deferred revenue | ||||
| Short long term debt | $1.69 | $1.31 | $0.8 | |
| Total current liabilities | $76.34 | $56.17 | $42.51 | $13.84 |
| Long term debt | $30.36 | $30.98 | $28.4 | |
| Total noncurrent liabilities | $132.99 | $30.98 | $29.82 | |
| Total debt | $32.05 | $32.29 | $29.21 | |
| Total liabilities | $209.32 | $87.15 | $72.33 | $13.84 |
| Shareholders' equity | ||||
| Retained earnings | -$48.49 | -$46.85 | -$17.58 | -$27.42 |
| Other shareholder equity | $8.88 | $0.85 | -$0.4 | $0 |
| Total shareholder equity | $464.91 | $417 | $239.21 | $200.25 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $153.39 | $145.82 | $143.19 | $132.09 |
| Cost of revenue | $19.99 | $18.89 | $17.01 | |
| Gross Profit | $133.54 | $125.83 | $124.3 | $115.09 |
| Operating activities | ||||
| Research & development | $24.91 | $26.88 | $22.89 | |
| Selling, general & administrative | $114.15 | $103.06 | $101.49 | |
| Total operating expenses | $146.78 | $142.54 | $135.18 | $124.39 |
| Operating income | -$16.72 | -$10.87 | -$9.3 | |
| Income from continuing operations | ||||
| EBIT | -$21.34 | -$16.01 | -$3.1 | |
| Income tax expense | $5.7 | $9.93 | $8.12 | $1.49 |
| Interest expense | $1.03 | $0.08 | $0.08 | $0.07 |
| Net income | ||||
| Net income | -$18.37 | -$31.35 | -$24.2 | -$4.67 |
| Income (for common shares) | -$31.35 | -$24.2 | -$4.67 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $493.63 | $383.47 | $276.98 | $139.67 |
| Cost of revenue | $59.07 | $44.51 | $24.76 | $13.11 |
| Gross Profit | $434.56 | $338.96 | $252.23 | $126.56 |
| Operating activities | ||||
| Research & development | $87.53 | $74.22 | $51.02 | $18.4 |
| Selling, general & administrative | $361.06 | $292.84 | $190.37 | $89.75 |
| Total operating expenses | $448.6 | $367.06 | $241.38 | $108.14 |
| Operating income | -$14.03 | -$28.1 | $10.84 | $18.42 |
| Income from continuing operations | ||||
| EBIT | $4.44 | -$25.89 | $10.98 | $14.92 |
| Income tax expense | $5.88 | $3.08 | $0.84 | |
| Interest expense | $0.2 | $0.29 | $0.29 | $1.14 |
| Net income | ||||
| Net income | -$1.64 | -$29.27 | $9.84 | $13.79 |
| Income (for common shares) | -$1.64 | -$29.27 | $9.84 | $13.79 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$31.35 | -$24.2 | -$4.67 | |
| Operating activities | ||||
| Depreciation | $4.74 | $4.62 | $3.45 | |
| Business acquisitions & disposals | $3.72 | -$240.42 | ||
| Stock-based compensation | $13.04 | $12.87 | $9.8 | |
| Total cash flows from operations | $11.51 | -$12.29 | $12.24 | |
| Investing activities | ||||
| Capital expenditures | -$4.58 | -$1.91 | -$2.4 | |
| Investments | -$4.9 | $41.07 | $183.1 | |
| Total cash flows from investing | -$0.85 | -$5.76 | $39.16 | -$59.72 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.1 | $4.13 | $0.28 | |
| Net borrowings | ||||
| Total cash flows from financing | $0.65 | -$2.75 | $1.01 | -$2.41 |
| Effect of exchange rate | $0.27 | -$0.01 | $0.11 | -$0.09 |
| Change in cash and equivalents | $2 | $2.98 | $28 | -$49.97 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$1.64 | -$29.27 | $9.84 | $13.79 |
| Operating activities | ||||
| Depreciation | $10.73 | $7.12 | $4.31 | $1.39 |
| Business acquisitions & disposals | -$240.42 | |||
| Stock-based compensation | $40.34 | $28.67 | $25.45 | $3.52 |
| Total cash flows from operations | $35.93 | -$13.97 | $25.49 | $1.91 |
| Investing activities | ||||
| Capital expenditures | -$6.2 | -$9.95 | -$13.64 | -$5.46 |
| Investments | $188.6 | -$185.26 | -$37.38 | -$49.98 |
| Total cash flows from investing | -$58.02 | -$195.22 | -$51.02 | -$55.44 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $10.74 | $183.63 | $6.43 | $164.83 |
| Net borrowings | -$20.25 | |||
| Total cash flows from financing | $1.17 | $177.14 | $4.07 | $144.12 |
| Effect of exchange rate | -$0.09 | -$0.48 | -$0.4 | |
| Change in cash and equivalents | -$21.01 | -$32.53 | -$21.86 | $90.59 |
News
Fundamentals
| Market cap | $4.67B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 58.44M |
| Revenue | $574.50M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$78.58M |
| Revenue Q/Q | 21.39% |
| Revenue Y/Y | 22.41% |
| P/E ratio | -59.47 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 8.13 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.34 |
|---|---|
| ROA | -11.62% |
| ROE | N/A |
| Debt/Equity | 0.45 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.77 |
| Quick ratio | 1.40 |